H
+ ion secretion into the gastric lumen is irreversibly inhibited. Similarly, histamine H2 antagonists prevent signaling of gastric acid production, thus, are oft en used to treat heartburn and dyspepsia. Elevated gastric pH can adversely aff ect concomitant oral medication bioavailability; therefore, careful examination of these interactions should be assessed when considering prescription of new drugs in patients taking ARAs.
Recent advances in the treatment of hepatitis C virus (HCV) infection have shown direct-acting antivirals (DAAs) to be highly eff ective for eradication of HCV in patients with various viral genotypes, both with and without cirrhosis. All DAAs for the treatment of HCV infection interact with drug metabolizing enzymes and/ or drug transporters and should be assessed for dose adjustment requirements or contraindications with concomitant medications ( 1 ) . In addition to the possibility of drug-drug interactions (DDIs) between ARAs and HCV DAAs, gastric pH can also eff ect DAA bioavailability due to increased or decreased pharmacokinetics (2) (3) (4) . As a result, sub-therapeutic levels of antiviral drugs may lead to failure to achieve sustained virologic response (SVR). Omeprazole has been reported to reduce the area under the concentrationtime curve (AUC) of ritonavir-boosted protease inhibitors by 75%; consequently, concomitant use of atazanavir, an HIV antiretroviral, and PPIs is considered contraindicated ( 2 ) . Th e HCV NS5A inhibitor ledipasvir has reduced solubility as pH increases, thus, the prescribing information for ledipasvir/sofosbuvir cautions against concomitant use of antacids, H2 antagonists, and PPIs, particularly doses of PPIs above the standard recommendation ( 4 ) . Th ough clinical trial data do not exist for ledipasvir/sofosbuvir co-administered with ARAs or PPIs, real-world data have emerged, indicating that PPI usage at baseline was associated with a higher rate of virologic failure ( 5 ) .
Th e HCV 3-DAA regimen of co-formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) and dasabuvir (DSV) with or without ribavirin (RBV) is approved for the treatment of chronic HCV genotype 1 infection in many countries including the United States, Japan, Canada, and countries in the European Union. Ritonavir and PTV are predominantly metabolized by CYP3A. Owing to inhibition of CYP3A activity, ritonavir boosting of protease inhibitors is common with antiretroviral agents and increases the AUC 5-to 80-fold, depending on the protease inhibitor boosted. Th e AUC of PTV is increased approximately 50-fold by ritonavir boosting, allowing for once-daily dosing ( 6 ) . DSV is predominantly metabolized by CYP2C8 with minor metabolism by CYP3A, and OBV is metabolized by amide hydrolysis. Finally, OBV, PTV, and DSV all inhibit UGT1A ( 7 ). In 24 DDI studies conducted with 31 compounds to evaluate the eff ects of OBV, PTV, ritonavir, and DSV on concomitant medications, and vice versa, co-administration with omeprazole did not change plasma exposures of any drug ( 8 ) .
Patients treated with OBV/PTV/r plus DSV with or without RBV achieved high rates of SVR 12 weeks post treatment (SVR12) in phase 3 trials ( 9-13 ). Unlike the phase 3 trials of other HCV DAA regimens (14) (15) (16) (17) , the six phase 3 trials of OBV/PTV/r plus DSV with or without RBV permitted concomitant use of ARAs, even at dosages higher than the prescribing information recommended dosage for each ARA or PPI (9) (10) (11) (12) (13) . In this analysis, we evaluated the integrated safety and effi cacy from phase 3 trials of this 3-DAA regimen with or without RBV in patients with HCV genotype 1 infection who were receiving a concomitant ARA.
METHODS

Study populations and treatments
Th is post hoc analysis included the effi cacy populations from patients enrolled in the six phase 3 trials, which included HCV treatment-naïve or peginterferon/RBV treatment-experienced patients without cirrhosis or with compensated cirrhosis. Sensitivity analyses were also conducted on the subset of patients who received the label-recommended regimen described in Supplementary Table 1 online. SAPPHIRE-I ( 9 ) and SAPPHIRE-II ( 10 ) were randomized, double-blind, placebo-controlled trials in noncirrhotic HCV genotype 1-infected patients with no prior HCV treatment history or treatment experienced with peginterferon/ RBV, respectively. PEARL-II was an open-label, randomized trial comparing the 3-DAA regimen with RBV or placebo in place of RBV in peginterferon/RBV treatment-experienced non-cirrhotic patients with HCV genotype 1b infection ( 13 ) . PEARL-III and PEARL-IV were double-blind randomized trials comparing the 3-DAA regimen with or without RBV in treatment-naïve patients without cirrhosis with genotype 1b and 1a infection, respectively ( 12 ) . All patients in these fi ve studies received 12 weeks of OBV/ PTV/r 25 mg/150 mg/100 mg once-daily plus DSV 250 mg twicedaily with or without weight-based RBV. Finally, TURQUOISE-II ( 11 ) was an open-label randomized trial comparing 12 vs. 24 weeks of OBV/PTV/r plus DSV and RBV in HCV genotype 1-infected patients with compensated cirrhosis. Study eligibility criteria have been published previously (9) (10) (11) (12) (13) .
Any medications received from the time of signing informed consent through HCV post-treatment day 30 were recorded. Allowed concomitant ARA use included antacids, H2 blockers (cimetidine, famotidine, ranitidine), and PPIs (omeprazole, esomeprazole, dexlansoprazole, lansoprazole, pantoprazole, and rabeprazole). For the purposes of these analyses, the standard dosage of omeprazole, esomeprazole, and rabeprazole was considered ≤20 mg/day, ≤30 mg/day for dexlansoprazole, ≤15 mg/day for lansoprazole, and ≤40 mg/day for pantoprazole; dosages above these thresholds were considered a high dosage.
Effi cacy and safety assessments
Virologic response was defi ned as a plasma HCV RNA below the lower limit of quantifi cation (LLOQ=25 IU/ml) using the Roche COBAS TaqMan real-time reverse transcriptase-PCR assay version 2.0 (Roche Molecular Systems, Pleasanton, CA), and the primary effi cacy assessment was SVR12. Effi cacy and safety were assessed in all patients of the studies' effi cacy populations, defi ned as all patients taking at least one dose of co-formulated OBV/PTV/r and DSV, and subgrouped by concomitant use (yes vs. no) of any ARA. In addition, subgroups defi ned by concomitant PPI use (yes vs. no) were also investigated. Rates of SVR12 were also evaluated in patients taking ARA dosages higher than the standard prescribing recommendations.
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Safety was assessed in all patients who received at least one dose of study drug. Treatment-emergent adverse events were collected from time of study drug initiation until 30 days post treatment. Serious adverse events were collected until the end of each study.
Statistical analysis
SAS (SAS Institute) for the UNIX operating system was used for all analyses. Intra-regimen baseline categorical variables were compared between patients taking concomitant ARAs or not using a Chi-square test or Fisher's exact test; continuous variables were compared using a Wilcoxon rank-sum test. 95% confi dence intervals (CIs) were calculated using the Wilson score method. Response rates in those receiving concomitant ARAs were compared with those not receiving concomitant ARAs using the Fisher's exact test. Rates were also compared in those taking standard vs. high dosages of ARAs using the Fisher's exact test.
Multivariate logistic regression analysis was performed on the effi cacy population to determine whether concomitant PPI use was associated with achievement of SVR12 or a predictor of virologic failure. Categorical variables included in the analysis were concom- ( 12, 13 ) . Serious adverse events observed in patients taking concomitant ARAs and OBV/PTV/r plus DSV with RBV did not have any evident commonality ( Supplementary Table 4 ) . Anemia, nausea, vomiting, and pneumonia were the only serious adverse events occurring serious adverse events were increased only in the ARA-taking patients receiving OBV/PTV/r plus DSV and RBV ( Table 2 ) . No severe or serious adverse events were reported in patients taking concomitant ARAs not receiving RBV (i.e., genotype 1b-infected patients). Commonly occurring adverse events, including fatigue, nausea, diarrhea, and dyspepsia, were more frequent in patients taking concurrent ARAs. Th e frequencies of laboratory abnormalities were comparable regardless of concomitant ARA use. Premature study drug discontinuation rates were similar regardless of in more than one patient. Only 7 (1.7%) patients taking concomitant ARAs had serious adverse events assessed as having a reasonable possibility of being related to study drug or RBV. Serious adverse events assessed as being related to RBV included anemia, stroke, acute renal failure, chronic obstructive pulmonary disease, lactic acidosis, and cellulitis. Among the 19 patients experiencing serious adverse events taking ARAs with HCV treatment, 10 had compensated cirrhosis. Th us, the serious adverse event rate in patients taking ARAs was 7.8% (10/128) among patients with cirrhosis compared with 3.2% (9/281) in patients without cirrhosis receiving treatment with or without RBV.
DISCUSSION
Antiviral development has focused on balancing therapeutic drug levels without undesirable side eff ects, at the same time considering concomitant drug interactions. ARA use over-the-counter and by prescription is very common, particularly in individuals with gastroesophageal refl ux disease, heartburn, or peptic ulcer disease. Orally administered medications, including new HCV DAAs, oft en rely on proper gastric or intestinal pH for optimal absorption. Despite the fact that omeprazole has been reported to reduce the AUC of ritonavir-boosted protease inhibitors, ARAs were not found to infl uence the drug exposures of the 3-DAA regimen of OBV/ PTV/r plus DSV based on numerous DDI studies ( 8 ) . Consistent with these observations, we report that this regimen with or without RBV achieved high SVR12 rates regardless of ARA/PPI use or PPI dosage in a large number of HCV genotype 1-infected patients, including those with cirrhosis who are prioritized for treatment. Emergence of resistance-associated variants is a function of both drug potency and drug exposure. Suboptimal absorption of antiviral drugs may provide opportunities for drug-resistant quasispecies or resistance-associated variants to emerge leading to HCV treatment failure. Concomitant administration of high PPI dosages and HCV DAAs that are sensitive to gastric pH may increase the risk for suboptimal drug exposures and the development of resistanceassociated variants. Although initial HCV treatments with peginterferon and RBV alone did not have drug resistance concerns, their eff ectiveness and safety profi les left much to be desired. Drug resistance concerns have become more evident with the development of HCV DAAs that specifi cally interact with diff erent non-structural proteins during viral replication. From our analysis, we observed high SVR12 rates in patients with pre-existing conditions necessitating higher than standard PPI dosages in whom pausing PPI therapy to facilitate HCV treatment may not be feasible. Among the common targets for HCV DAAs (i.e., NS3, NS5A, and NS5B), NS5A resistance-associated variants have been identifi ed as being particularly persistent ( 18, 19 ) , and are associated with reduced SVR rates when present at baseline or upon retreatment. ( 20, 21 ) Reports have shown that 94-96% of NS5A resistance-associated variants persist up to 96 weeks aft er relapse ( 18, 19 ) , thus, reducing the risk of developing resistance should be a priority until suffi cient retreatment options are available. Accordingly, an HCV treatment option that permits concomitant use of higher PPI dosages is desirable for patients requiring higher-than-standard PPI doses.
Ledipasvir, an NS5A inhibitor, has reduced solubility as gastric pH increases that can lead to decreased drug exposure ( 4 ) . Although concomitant use of ARAs was specifi cally excluded within phase 2 and 3 studies of ledipasvir/sofosbuvir, the label for ledipasvir/sofosbuvir recommends separating antacid administration by at least 4 h, H2 antagonists by 12 h, and omeprazole or equivalent PPI doses no higher than 20 mg. Patients taking ARAs and PPIs were also excluded from phase 2 and 3 studies of the HCV regimen containing the NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir ( 16, 22 ) . Approval of grazoprevir/elbasvir is expected in early 2016; thus, the label recommendations for concomitant ARA use remain unknown. Because ARAs were excluded from phase 3 registrational trials for these two HCV regimens, real-world data will be needed to elucidate ARA co-administration safety and eff ectiveness. A logistic regression analysis from the HCV TARGET registry, which included data from over 1,000 patients receiving ledipasvir/sofosbuvir regimens, identifi ed PPI use at baseline as a negative predictor for SVR ( 5 ) . Rates of SVR12 were 98.3% in patients without PPI use at baseline compared with 92.7% in patients taking PPIs at baseline ( 5 ). In contrast, concomitant PPI use with OBV/PTV/r plus DSV with or without RBV was not found to be a predictor of lower SVR12 rates or virologic failure by logistic regression.
In patients treated with OBV/PTV/r plus DSV with RBV, SVR12 rates were similar irrespective of whether concomitant ARAs including standard and high-dose PPIs were taken or not. Th is observation was despite the fact that, on average, patients taking ARAs were older, had a higher BMI, and more oft en had genotype 1a infection and cirrhosis. Th ese baseline population diff erences may have played a role in the increased rates of adverse events recorded in patients taking concomitant ARAs, particularly the diff erence in proportion of patients with cirrhosis in whom advanced liver disease is associated with higher rates of adverse events ( 11, 23 ) . In addition, a higher proportion of patients receiving concomitant ARAs were enrolled at sites within the United States where reporting of adverse events has been observed to be higher among American populations in studies with the 3-DAA regimen ( 12 ) . Not surprisingly, some events (e.g., dyspepsia, nausea, and diarrhea) were reported more oft en in individuals taking ARAs at baseline who had a higher prevalence of baseline gastric hyperacidity (i.e., gastroesophageal refl ux disease, gastritis, peptic ulcer disease, and dyspepsia). Th e majority of serious adverse events were assessed to have no reasonable possibility of being related to study drug or RBV. Overall, the rate of treatment discontinuation due to adverse events was low and laboratory abnormalities were similar regardless of concomitant ARA use.
In conclusion, the fi ndings of this post hoc analysis provide reassurance that the co-administration of OBV/PTV/r plus DSV with ARAs and PPIs does not negatively aff ect the chance for viral eradication. High SVR rates were achieved despite advanced fi brosis and concomitant ARA or PPI use.
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